Edition:
United Kingdom

Kura Oncology Inc (KURA.OQ)

KURA.OQ on NASDAQ Stock Exchange Global Select Market

19.30USD
15 Aug 2018
Change (% chg)

$-0.50 (-2.53%)
Prev Close
$19.80
Open
$19.70
Day's High
$19.70
Day's Low
$19.23
Volume
44,712
Avg. Vol
69,074
52-wk High
$24.00
52-wk Low
$5.90

Latest Key Developments (Source: Significant Developments)

Kura Oncology Q2 Loss Per Share $0.45
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Kura Oncology Inc ::KURA ONCOLOGY REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.45.Q2 EARNINGS PER SHARE VIEW $-0.45 -- THOMSON REUTERS I/B/E/S.BELIEVES EXISTING CAPITAL RESOURCES SUFFICIENT TO FUND CURRENT OPERATIONS THROUGH 2021.KURA ONCOLOGY - BIOMARKER-ENRICHED PHASE 2 TRIAL OF TIPIFARNIB IN PERIPHERAL T-CELL LYMPHOMA DATA EXPECTED BY YEAR END.  Full Article

Kura Oncology Says Gave Notice To Terminate Amended & Restated Sales Agreement That Co Entered Into With Cowen And Company On March 12
Monday, 2 Jul 2018 

July 2 (Reuters) - Kura Oncology Inc ::KURA ONCOLOGY SAYS GAVE NOTICE TO TERMINATE AMENDED & RESTATED SALES AGREEMENT THAT CO ENTERED INTO WITH COWEN AND COMPANY ON MARCH 12 - SEC FILING.KURA ONCOLOGY INC - TERMINATION OF THE SALES AGREEMENT WILL BE EFFECTIVE JULY 12, 2018.  Full Article

Kura Oncology files for mixed shelf offering of up to $200 mln - SEC filing‍​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Kura Oncology Inc :Kura Oncology Inc - files for mixed shelf offering of up to $200 million - SEC filing‍​.  Full Article

Kura Oncology reports third quarter 2017 financial results
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Kura Oncology Inc ::Kura Oncology reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.38.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.  Full Article

KURA ONCOLOGY ‍CONFIRMS PARTIAL RESPONSES OBSERVED IN PATIENTS WITH HRAS MUTANT HNSCC IN TRIAL
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Kura Oncology Inc :KURA ONCOLOGY LEAD CANDIDATE TIPIFARNIB SHOWS DURABLE ANTI-TUMOR ACTIVITY IN HRAS MUTANT HEAD AND NECK CANCER IN AACR-NCI-EORTC UPDATE.‍CONFIRMED PARTIAL RESPONSES OBSERVED IN FOUR OUT OF SIX PATIENTS WITH HRAS MUTANT HNSCC IN TRIAL​.BASED ON POSITIVE RESULTS FROM PHASE 2 TRIAL, CO PLANS TO INITIATE A REGISTRATION-ENABLING STUDY IN HRAS MUTANT HNSCC IN 2018​.  Full Article

BRIEF-Kura Oncology Reports Qtrly Loss Per Share Of $0.46

* KURA ONCOLOGY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE